Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study
Catherine Cordonnier, Per Ljungman, Christine Juergens, Johan Maertens, Dominik Selleslag, Vani Sundaraiyer, Peter C Giardina, Keri Clarke, William C Gruber, Daniel A Scott, Beate Schmoele-Thoma, 3003 Study Group, Catherine Cordonnier, Per Ljungman, Christine Juergens, Johan Maertens, Dominik Selleslag, Vani Sundaraiyer, Peter C Giardina, Keri Clarke, William C Gruber, Daniel A Scott, Beate Schmoele-Thoma, 3003 Study Group
Abstract
Background: Life-threatening Streptococcus pneumoniae infections often occur after hematopoietic stem cell transplant (HSCT); vaccination is important for prevention.
Methods: In an open-label study, patients (n = 251) 3-6 months after allogeneic HSCT received 3 doses of 13-valent pneumococcal conjugate vaccine (PCV13) at 1-month intervals, a fourth dose 6 months later, and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later. Immunogenicity at prespecified time points and vaccine safety were assessed.
Results: In the evaluable immunogenicity population (N = 216; mean age, 37.8 years), geometric mean fold rises (GMFRs) of immunoglobulin G geometric mean concentrations from baseline to postdose 3 showed significant increases in antibody levels across all PCV13 serotypes (GMFR range, 2.99-23.85; 95% confidence interval lower limit, >1); there were significant declines over the next 6 months, significant increases from predose 4 to postdose 4 (GMFR range, 3.00-6.97), and little change after PPSV23 (GMFR range, 0.86-1.12). Local and systemic reactions were more frequent after dose 4. Six patients experienced serious adverse events possibly related to PCV13 (facial diplegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack of vaccine efficacy after dose 3 leading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barré syndrome), or PPSV23 (cellulitis). There were 14 deaths, none related to study vaccines.
Conclusions: A 3-dose PCV13 regimen followed by a booster dose may be required to protect against pneumococcal disease in HSCT recipients. Dose 4 was associated with increased local and systemic reactions, but the overall safety profile of a 4-dose regimen was considered acceptable.
Clinical trials registration: NCT00980655.
Keywords: 13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; Streptococcus pneumoniae infections; hematopoietic stem cell transplant.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
Figures
References
- Engelhard D, Cordonnier C, Shaw PJ et al. . Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002; 117:444–50.
- Kumar D, Humar A, Plevneshi A et al. . Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant 2008; 41:743–7.
- Torda A, Chong Q, Lee A et al. . Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2014; 16:751–9.
- Tomblyn M, Chiller T, Einsele H et al. . Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143–238.
- Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Recomm Rep 2000; 49(RR-10):1–127.
- D'Orsogna LJ, Wright MP, Krueger RG et al. . Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells. Biol Blood Marrow Transplant 2009; 15:795–803.
- Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore) 2007; 86:69–77.
- Ada G. Vaccines and vaccination. N Engl J Med 2001; 345:1042–53.
- Clutterbuck EA, Lazarus R, Yu LM et al. . Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408–16.
- Cordonnier C, Labopin M, Chesnel V et al. . Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009; 48:1392–401.
- Meisel R, Kuypers L, Dirksen U et al. . Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:2322–6.
- Molrine DC, Antin JH, Guinan EC et al. . Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003; 101:831–6.
- Pao M, Papadopoulos EB, Chou J et al. . Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2008; 14:1022–30.
- Ljungman P, Engelhard D, de la Camara R et al. . Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35:737–46.
- Ljungman P, Cordonnier C, Einsele H et al. . Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44:521–6.
- Ljungman P, Small TN; Vaccination Recommendations Writing Group. Update to vaccination guidelines. Biol Blood Marrow Transplant 2010; 16:1608–9.
- Pilishvili T, Lexau C, Farley MM et al. . Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32–41.
- Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29:9127–31.
- Kaplan SL, Barson WJ, Lin PL et al. . Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203–7.
- Singleton R, Wenger J, Klejka JA et al. . The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J 2013; 32:257–63.
- Hak E, Grobbee DE, Sanders EA et al. . Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378–83.
- Bonten MJM, Huijts SM, Bolkenbaas M et al. . Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114–25.
- Tomczyk S, Bennett NM, Stoecker C et al. . Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822–5.
- Wernette CM, Frasch CE, Madore D et al. . Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10:514–9.
- Romero-Steiner S, Libutti D, Pais LB et al. . Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415–22.
- Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011; 29:7207–11.
- Liu X, Wang S, Sendi L, Caulfield MJ. High-throughput imaging of bacterial colonies grown on filter plates with application to serum bactericidal assays. J Immunol Methods 2004; 292:187–93.
- World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines—proposed replacement of TRS 927, Annex 2, ECBS, 19–23 October 2009. Geneva, Switzerland: WHO, 2009.
- Hu BT, Yu X, Jones TR et al. . Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin Diagn Lab Immunol 2005; 12:287–95.
- Vernacchio L, Romero-Steiner S, Martinez JE et al. . Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis 2000; 181:1162–6.
- Bryant KA, Frenck RW, Gurtman A et al. . Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18 to 49 years, naive to 23-valent pneumococcal polysaccharide vaccine. In: European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27–30 April 2013.
- Jackson LA, Gurtman A, van Cleeff M et al. . Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577–84.
- Rubin LG, Levin MJ, Ljungman P et al. . 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:309–18.
- Frenck R Jr, Thompson A, Senders S et al. . 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naive to 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014; 33:183–9.
- Schwarz TF, Flamaing J, Rumke HC et al. . A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years. Vaccine 2011; 29:5195–202.
- Cordonnier C, Labopin M, Chesnel V et al. . Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 2010; 28:2730–4.
Source: PubMed